Elixiron Immunotherapeutics (Cayman) Limited (TPEX:7871)

Revenue by Segment

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023
New Drug Research and Development	50.29M	803.00K	25.70M
New Drug Research and Development Growth	6162.39%	-96.88%	-
Total	50.29M	803.00K	25.70M
Total Growth	6162.39%	-96.88%	-

Revenue by Geography

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023
United State of America	50.29M	803.00K	25.07M
United State of America Growth	6162.39%	-96.80%	-
Switzerland	-	-	624.00K
Total	50.29M	803.00K	25.70M
Total Growth	6162.39%	-96.88%	-

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Jul 4, 2026

Data Sources Report a data error